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Hypertrophic cardiomyopathy in young Maine
Coon cats caused by the p.A31P cMyBP-C
mutation - the clinical significance of having
the mutation
Mia TN Godiksen1,2, Sara Granstrøm1,2, Jørgen Koch2, Michael Christiansen1*
Abstract
Background: In Maine Coon (MC) cats the c.91G > C mutation in the gene MYBPC3, coding for cardiac myosin
binding protein C (cMyBP-C), is associated with feline hypertrophic cardiomyopathy (fHCM). The mutation causes a
substitution of an alanine for a proline at residue 31 (p.A31P) of cMyBP-C. The pattern of inheritance has been
considered autosomal dominant based on a single pedigree. However, larger studies are needed to establish the
significance of cats being heterozygous or homozygous for the mutation with respect to echocardiographic indices
and the probability of developing fHCM. The objective of the present study was to establish the clinical significance
of being homozygous or heterozygous for the p.A31P cMyBP-C mutation in young to middle-aged cats.
Methods: The cohort consisted of 332 MC cats, 282 cats < 4 years (85%). All cats were examined by 2-D and M-
mode echocardiography. DNA was extracted from blood samples or buccal swabs and screened for the p.A31P
cMyBP-C mutation in exon 3 of the gene, using polymerase chain reaction followed by DNA sequencing.
Results: The fHCM prevalence was 6.3% in the cohort. Eighteen cats were homozygous and 89 cats were
heterozygous for the mutation. The odds ratio for having fHCM for homozygous cats was 21.6 (95% confidence
interval 7.01-66.2) - when the group of equivocal cats was categorized as non-affected. Overall, 50% of the cats
that were homozygous for the mutation had fHCM. p.A31P heterozygosity was not associated with a significant
odds ratio for fHCM. In cats in the 4 to 6 years of age range a similar, non significant, odds ratio was seen in
heterozygous cats. Only two cats over four years were homozygous and both were diagnosed with fHCM.
Conclusion: As there is no significant odds ratio associated with being heterozygous for the pA31P cMyBP-C
mutation at this age, the mutation must have a very low penetrance in this group. From our data it would appear
that most MC cats that develop fHCM due to the p.A31P mutation prior to the age of approximately 6 years do so
because they are homozygous for this mutation.
Background
Hypertrophic cardiomyopathy (HCM), in humans, is a
primary disorder of the myocardium that most com-
monly results from mutations in genes that encode for
sarcomeric proteins. Feline HCM (fHCM) is a clinically
heterogeneous disorder which is characterised by loca-
lized or generalized concentric left ventricular
hypertrophy and diastolic dysfunction [1-7]. Affected
cats may progress into congestive heart failure, throm-
boembolic events or sudden cardiac death [8]. Not
much is known about the genetics underlying fHCM
and presently only two mutations have been found [4,5].
The Maine Coon (MC) cat is predisposed to fHCM.
The true prevalence within the breed is not known,
however it may be as high as 9.5-26.3% [9]. Similar to
human HCM, fHCM in MC cats exhibits incomplete
penetrance and variable expressivity; thus, it is possible
to find phenotypically normal mutations carriers [10,11].
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Diagnosis of fHCM in MC cats should ideally be based
on a positive family history, and a thorough echocardio-
graphic assessment of several imaging planes of the
heart with follow-ups. Genetic testing is currently of
limited utility, as the clinical significance of being a
mutation carrier has not been completely established.
fHCM in MC cats is an excellent spontaneous animal
model for human HCM, as the characteristics of the dis-
ease mimic the ones seen in human patients including
the increased risk of sudden death [7,12].
Mutations in the MYBPC3 gene, encoding the sarco-
mere cardiac protein Myosin Binding Protein C
(cMyBP-C), are associated with HCM in human and
fHCM in MC and Ragdoll cats [4,5,13]. More than 240
HCM-causing mutations in the cMyBP-C protein have
been reported from studies of human HCM [14], and
cMyBP-C mutations are responsible for ~ 30% of all
human HCM cases [3,13,15].
Meurs et al. [4] identified a disease-causing missense
mutation (c.91G > C) in the feline MYBPC3 gene in a
colony of MC cats with fHCM. The mutation causes the
substitution of an alanine for a proline at residue 31 (p.
A31P) of the cMyBP-C protein. Affected cats exhibit a
broad phenotypic variation from mild to severe fHCM.
Some cats have died before four years of age, where
others were still alive at 8-12 years of age [4]. The fre-
quency of this mutation has later been reported to be
34% among MC cats [16].
The objective of this study was to investigate the rela-
tionship between fHCM and MC cats heterozygous and
homozygous for the p.A31P cMyBP-C mutation in a
large cohort of MC cats. This study may contribute
recommendations to MC breeding programs concerning
the control of fHCM.
Methods
Clinical examinations
A cohort of 332 MC cats was prospectively included in
the study at the Department of Small Animal Clinical
Sciences, University of Copenhagen, Denmark. The
cohort consisted of MC cats from MC breeders and
owners who gave informed consent to participate. The
study was approved by the ethics committee of the
department. All cats were examined by 2-D and M-
mode echocardiography in right lateral recumbency and
imaged from below by one trained observer using a
Vivid 7 Dimension ultrasonographic system equipped
with a 10 S phased array transducer (4-11.5 MHz; GE
Healthcare, Horten, Norway). Measurements of the left
ventricle were obtained from M-mode imaging in stan-
dard echocardiographic right parasternal long axis four-
chamber and short axis views at level of the chordae
tendineae and according to the recommendations of the
Echocardiography Committee of the Specialty of
Cardiology, American College of Veterinary Internal
Medicine and the American Society of Echocardiogra-
phy, respectively [17,18]. The M-mode values of left
ventricular dimensions were confirmed by measure-
ments of multiple left ventricular wall segments from
several 2-D views and cats were classified to have fHCM
if the maximum diastolic wall thickness in any segment
exceeded 5.5 mm in > 50% of segment length. Presence
of an enlarged left atrium, systolic anterior motion of
the septal leaflet of the mitral valve, left ventricular end-
systolic cavity obliteration and enlarged papillary mus-
cles further strengthened the diagnosis of fHCM. Cats
were considered to be fHCM negative if the diastolic
‘left ventricular free wall’ (LVFW) and diastolic ‘inter-
ventricular septum’ (IVS) measured < 5 mm and no
other cardiac abnormalities could be found. Cats were
categorized as equivocal if they had a normal wall thick-
ness (< 5.5 mm) and displayed papillary muscle
hypertrophy.
An fHCM screening form, from PawPeds international
health programme [19], was filled out immediately after
the examination and all images were stored digitally for
later off-line analysis. All values represented the average
of three consecutive beats. The method used to measure
left atrium and aorta has previously been described in
dogs [20].
The p.A31P cMyBP-C genotype of all cats was
unknown to the observer at the echocardiographic
examination and later offline analysis.
Laboratory studies
DNA was extracted from ethylenediaminetetraacetic
acid stabilized blood or full blood using automated
DNA purification by MAXWELL® (Promega, Nacka,
Sweden) according to manufacturer’s instructions.
Where blood was not available (3% of all samples),
DNA was obtained and extracted using a MasterAmp™
Buccal Swab Kit (VWR & Bie & Berntsen, Herlev, Den-
mark) after the manufacturer’s instructions. The feline
MYBPC3 gene sequence was obtained from Ensembl
(ENSFCAG00000002530) [21]. Amplification of genomic
DNA was performed using the following primer set:
exonic forward primer 5’-agccttcagcaagaagcca-3’ and
exonic reverse primer 5’-caaacttgaccttggaggagc-3’. The
polymerase chain reaction (PCR) was carried out with 1
μl genomic DNA (~ 50 ng/μl) in a volume of 25 μl con-
taining 1 μl 20 pmol/μl primer mix (DNA technology
AS, Aarhus, Denmark) 2.5 μl 10 × PCR buffer (15 mM
MgCl2) (Qiagen, Copenhagen, Denmark), 0.5 μl dNTP
mix 10 mM solution (GE Healthcare Life Sciences,
Brondby, Denmark), 0.2 μl Hot star polymerase (Qiagen,
Copenhagen, Denmark) and 5 μl Q-buffer (Qiagen,
Copenhagen, Denmark). Samples were heat activated at
95°C for 15 min followed by 35 cycles: 95°C for 30 sec,
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58°C for 30 sec, 72°C for 1 min and a final step of elon-
gation (72°C for 7 min). PCR products were visually ver-
ified and thereafter treated with Exonuclease I
(Medinova Scientific, Glostrup, Denmark). Mutation
screening was carried out by direct DNA sequencing
using BigDye® technology (GE Healthcare Life Sciences,
Brondby, Denmark) on an ABI 3730 sequencer (Applied
Biosystems, Naerum, Denmark). PCR products were
sequence in both directions using the respective forward
and reverse primers.
Statistics
The Chi-square test (c2) was used to evaluate if the gen-
otype distribution was in Hardy-Weinberg equilibrium, a
P-value < 0.05 indicated significance. The clinical signifi-
cance of the p.A31P cMyBP-C protein mutation was
determined by looking at the probability of developing
fHCM when comparing the heterozygous and the
homozygous mutation carriers with the wild type cats
using odds ratio calculation and the 95% confidence
interval (95% Cfi) was established.
When data were plotted, the measurements of age,
weight, diastolic IVS and LVFW, systolic LVFW and the
ratio of left atria over aorta (LA/Ao) all followed a non-
normal distribution, thus Kruskal-Wallis test was used
to compare the medians of the data. A P-value < 0.05
was considered statistically significant.
Spearman correlation was used to test if diastolic IVS
and LVFW correlated with age for cats being homozy-
gous for the mutation (Figure 1), a P-value < 0.05 was
considered significant.
Results
The Maine Coon cohort
The MC cohort consisted of 332 cats, 118 males with a
median age of 1.5 years of age (95% range 0.7; 6.0) and
a median weight of 6.0 kg (95% range 4.0; 8.8) and 214
queens with a median age of 2.0 years (95% range 1.0;
5.5) and a median weight of 4.4 kg (95% range 3.4; 6.0).
Presentation of the cohort can be seen in Tables 1 and
2, where the cats were categorized according to their
fHCM clinical presentation and p.A31P cMyBP-C,
respectively.
The cats were categorized into three groups: fHCM
positive, fHCM negative and equivocal cats. The fHCM
positive group consisted of 21 cats (14 males). The equi-
vocal group consisted of 26 cats (14 males) and the
remaining 285 cats were classified as fHCM negative (90
males). No significant differences in age was found
between the three groups (P > 0.05). The weight of
fHCM positive cats was significantly higher than fHCM
negative cats (P < 0.05), no difference in weight was
found between the fHCM cats and cats with equivocal
status (P > 0.05).
Characterisation of the fHCM positive MC cats
Twenty-one cats were diagnosed with fHCM, making
the prevalence 6.3% - and 14.2% when the equivocal
group was added to the fHCM affected group. However,
for the male MC cats alone the fHCM prevalence was
11.9% and a further 11.9% were categorized as equivocal
(a total of 23.7%). See Table 3 for genotype and pheno-
type distribution.
In total, 13 fHCM positive cats (62%) had a cardiac
murmur (3 with grade I, 4 with grade II, 5 with grade
III, 1 with grade IV). Systolic anterior movement (SAM)
of the mitral valve was observed in 52% of fHCM posi-
tive cats and end-systolic cavity obliteration was
observed in 43% of fHCM positive cats. The diagnostic
findings for the three groups are summarized in
Table 1. The wall thickness and the inner diameter of
the ventricle given in Tables 1, 2 and 4 reflect standard
measurement with M-mode echocardiography from a
right parasternal short axis view at level of the chordae
tendinae. Localized and asymmetrical thickening of the
myocardium can be missed with a standard M-mode
projection in all cats, thus they were also measured by
2-D echocardiography. The echocardiographic measure-
ments and M-mode echocardiograms of hearts from an
fHCM positive and a negative MC, respectively, are
shown in Figures 2 and 3.
The equivocal cats were mainly characterized by nor-
mal wall thickness (< 5.5 mm) and papillary muscle size,
with or without end-systolic cavity obliteration. In odds
ratio calculations the equivocal cats were first added to
the group of fHCM positive cats and afterward added to
the group of fHCM negative cats for the same
calculations.
p.A31P cMyBP-C genotyping
All cats were genotyped with respect to the cMyBP-C
mutation (Table 3). Eighteen MC cats were homozy-
gous, 89 MC cats were heterozygous and 225 MC cats
were wild type (no mutation). 10 out of 21 MC cats
with an fHCM diagnosis did not carry the mutation.
The histogram in Figure 4A shows the fraction of
fHCM and equivocal cases in the three different
genotypes.
The mutated MYBPC3 gene-allele (c.91C) was found
to be the minor allele with an allele frequency of 0.19.
The genotype distribution was not in Hardy-Weinberg
equilibrium (P <0.05, c2 test).
The significance of the p.A31P cMyBP-C mutation
Odds ratio calculations were used to determine the
probability of developing fHCM in all cats with the
mutation. The odds ratio was calculated for heterozy-
gous and homozygous carriers of p.A31P cMyBP-C
between fHCM affected and non-affected cats, using
Godiksen et al. Acta Veterinaria Scandinavica 2011, 53:7
http://www.actavetscand.com/content/53/1/7
Page 3 of 11
Figure 1 The correlation with age and diastolic IVS and LVFW measurements as a function of c.91C MYBPC3 alleles. Top: Plot of
diastolic IVS correlation with age as a function numbers of c.91C MYBPC3 alleles. There was tendency to an increasing effect of p.A31P cMyBP-C
homozygosity with age, though the tendency was not significant, r = 0.41, P = 0.09. There was only a low effect of being p.A31P cMyBP-C
heterozygous, r = 0.09, P = 0.4. Bottom: Plot of diastolic LVFW correlation with age as a function of numbers of MYBPC3 c.91C alleles. The
tendency was more weak than seen above, r = 0.2, P = 0.50. Red indicates the cMyBP-C wild type coordinates and the corresponding line of
tendency. Green indicates p.A31P cMyBP-C heterozygous coordinates and the corresponding line of tendency. Blue indicates p.A31P cMyBP-C
homozygous where and the corresponding line of tendency. Figure abbreviations: IVSd: diastolic interventricular septum, LVFWd: diastolic left
ventricle free wall.
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mutation wild type cats as a control group. The odds
ratio of having fHCM (or being equivocal) for all cats
carrying the C allele (c.91C) was found to be 1.9 (95%
Cfi: 1.0; 3.6). The odds ratios of having fHCM for
homozygous and heterozygous mutation carriers were
12.1 (95% Cfi: 4.3; 33.9) and 1.0 (95% Cfi: 0.5; 2.1),
respectively. The same odds ratio calculations, with the
equivocal cats added to the group of fHCM negative
cats revealed an odds ratio for cats carrying the C allele
(c.91C) to be 2.5 (95% Cfi: 1.0; 6.0). For homozygous
and heterozygous cats the odds ratios were found to be
21.6 (95% Cfi: 7.0; 66.2) and 0.5 (95% Cfi: 0.1; 2.3),
respectively.
The fHCM prevalence for the disease was found to be
2.4% in heterozygous cats and 9.1% of heterozygous cats
were classified as equivocal. Among p.A31P cMyBP-C
homozygous MC cats, 50% had fHCM and a further 11%
were categorized as equivocal (Table 3). Table 5 gives an
overview of the fHCM penetrance and the fHCM odds
ratio of the group of heterozygous cats, the homozygous
cats and both combined. The fHCM odds ratios of all three
categories were compared to cMyBP-C wild type cats.
Table 1 Presentation of Main Coon cat cohort
fHCM status
fHCM Equivocal Negative
N, gender distribution 21 (14 males) 26 (14 males) 285 (90 males)
Age, y (median, 95% range) 2.0, 1.0; 11.0 2.0, 0.5; 5.5 2.0, 1.0; 5.3
Weight, kg (median, 95% range) 6.2, 4.5; 7.8 5.5, 3.5; 8.2 4.5, 3.4; 7.0
IVSd, mm (median, 95% range) 6.0, 3.4; 6.9 3.5, 2.7; 5.1 3.7, 2.8; 4.5
LVIDd, mm (median, 95% range) 15.0, 11.1; 19.0 15.5, 12.3; 19.0 15.7, 12.7; 19.0
LVFWd, mm (median, 95% range) 6.2, 4.9; 9.9 4.0, 2.8; 5.5 3.8, 2.8; 4.8
IVSs, mm (median, 95% range) 8.5, 5.8; 11.3 6.4, 4.5; 8.1 6.4, 4.8; 8.0
LVIDs, mm (median, 95% range) 7.8, 3.9; 11.3 8.2, 6.3; 13.0 9.1, 6.1; 12.5
LVFWs, mm (median, 95% range) 9.2, 6.8; 13.4 7.3, 6.0; 8.7 6.7, 5.0; 8.2
LA/Ao, (median, 95% range) 1.2, 1.0; 3.0 1.0, 1.0; 1.2 1.0, 0.9; 1.2
% with murmur 62 14 1
% with SAM 52 0 0
% with obliteration 43 43 < 1
% with hypertrophic papillary muscle 76 73 1
% with increased LA 14 4 < 0.5
IVSd: diastolic intraventricular septum, LVIDd: diastolic left ventricular inner diameter, LVFWd: diastolic left ventricular free wall, IVSs: systolic intraventricular
septum, LVIDs: systolic left ventricular inner diameter, LVFWs: systolic left ventricular free wall, LA/Ao: left atrium over aorta.
Table 2 Presentation of the Main Coon cat cohort categorised in groups depending on the A31P CMYBP-C genotype
cMyBP-C p.A31P genotype P-value mutation negative vs
Homozygous (C/C) Heterozygous (G/C) Wild type (G/G) Homozygous Heterozygous
n, gender distribution 18 (12 males) 89 (25 males) 225 (81 males) - -
Age, y (median, 95% range) 1.5, 1.0; 11.0 2.0, 0.9; 5.9 1.7, 1.0; 5.0 0.48 0.14
Weight, kg (median, 95% range) 5.9, 3.4; 7.0 4.6, 3.5; 7.8 4.5, 3.4; 7.2 0.04 0.32
IVSd, mm (median, 95% range) 4.2, 3.2; 9.1 3.7, 2.8; 5.5 3.7, 2.8; 5.1 0.002 0.70
LVIDd, mm (median, 95% range) 15.6, 10.2; 18.4 15.9, 12.8; 19.0 15.6, 12,3; 19.0 0.88 0.59
LVFWd, mm (median, 95% range) 5.1, 3.6; 11.0 3.7, 2.7; 4.8 4.0, 2.9; 5.0 < 0.001 0.10
IVSs, mm (median, 95% range) 7.8, 5.0; 11.3 6.3, 4.8; 8.1 6.4, 4.8; 8.4 0.04 0.29
LVIDs, mm (median, 95% range) 8.8, 4.0; 13.0 9.0, 5.7; 12.6 9.0, 6.1; 12.4 0.23 0.80
LVFWs, mm (median, 95% range) 8.9, 5.5; 13.4 6.7, 5.1; 8.3 6.7, 5.1; 8.7 0.016 0.90
LA/Ao, (median, 95% range) 1.1, 0.9; 4.0 1.0, 0.9; 1.1 1, 0.9; 1.2 0.0004 0.31
% with murmur 50 2 4
% with SAM 44 1 0
% with obliteration 44 4 5
% with hypertrophic papillary muscle 56 9 8
% with increased LA 22 0 < 1
IVSd: diastolic intraventricular septum, LVIDd: diastolic left ventricular inner diameter, LVFWd: diastolic left ventricular free wall, IVSs: systolic intraventricular
septum, LVIDs: systolic left ventricular inner diameter, LVFWs: systolic left ventricular free wall, LA/Ao: left atrium over aorta.
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The fHCM diagnostic parameters compared between
groups of the three different genotypes are summarized
in Table 2.
Figure 1 represents plots of the echocardiographic
measurements of diastolic IVS and LVFW as a function
of age and p.A31P cMyBP-C heterozygous or homozy-
gous status. There was no significant correlation
between age and diastolic IVS or LVFW in cats hetero-
zygous for the mutation or in wild type cats. There was
a tendency for diastolic IVS (r = 0.4, P = 0.09) to
increase with age for cats homozygous for the mutation.
A small cohort consisting of all cats over 4 years of
age (with a median age of 4.9 years, 95% range 4; 8.1)
was used to examine the significance of being affected
by the p.A31P cMyBP-C mutation in middle-aged cats.
The small cohort consisted of 50 cats; six of which had
been positively diagnosed with fHCM. Within this
cohort, we identified 14 cats being heterozygous and
two cats being homozygous for the mutation. One equi-
vocal cat and one fHCM positive cat were among the
heterozygous cats and both homozygous cats were
fHCM positive. The odds ratio of being fHCM positive
for heterozygous mutation carriers over four years of
age was found to be 0.64 (95% Cfi 0.1-3.6) - when the
equivocal cats were categorized as fHCM affected. Cate-
gorizing the equivocal cats as non-affected resulted in
an odds ratio of 0.8 (95%Cfi: 0.1-8.4). The relative distri-
bution of fHCM and equivocal cats as a function of the
p.A31P cMyBP-C genotype is shown in Figure 4B. Table
4 presents the echocardiographic measurements corre-
sponding to either heterozygous or non-mutation
carriers.
Discussion
We investigated the clinical significance of being hetero-
zygous or homozygous for the p.A31P cMyBP-C muta-
tion in a cohort of young MC cats. We did not find a
significant odds ratio for the development of fHCM for
cats heterozygous for the mutation. However, we did find
a significantly high odds ratio for cats homozygous for
the mutation and so a high probability for developing
fHCM. Based on these results the penetrance in hetero-
zygous cats must be considered very low in young cats
and high in young cats homozygous for the mutation.
Additionally, we found that diastolic IVS thickness had
a tendency to progress with age in p.A31P cMyBP-C
homozygous cats compared to heterozygous and wild
type cats. A reduced number of homozygous cats due to
fHCM related death might explain why the correlation
between increasing age and increasing diastolic IVS or
LVFW was not significant.
To compensate for the young mean age of the cohort
we investigated a smaller group consisting of 50 cats, all
over four years of age with a median of 4.9 years of age
(95% range: 4; 8.1). In this small cohort, 14 cats were
heterozygous and a further two were homozygous.
Table 3 Distribution of the fHCM negative, the equivocal
and the fHCM positive cats in respect to p.A31P
genotype
Negative Equivocal fHCM
Wild type (G/G) 200 16 10
Heterozygous (G/C) 78 8 2
Homozygous (C/C) 7 2 9
Table 4 Echocardiographic characteristics for cats over 4 years of age
cMyBP-C p.A31P genotype P-value
Heterozygous (G/C) Wild type (G/G)
n, gender distribution 14 (4 males) 34 (14 males) -
Age, y (median, 95% range) 5.7, 4.0; 9.0 4.5, 4.0; 6.0 0.17
Weight, kg (median, 95% range) 6.0, 4.5; 8.8 5.1, 8.7; 3.5 > 0.05
IVSd, mm (median, 95% range) 3.7, 3.1; 6.2 3.9, 2.9; 6.2 0.40
LVIDd, mm (median, 95% range) 16.6, 13.8; 19.3 15.9, 13.8; 1.9 0.20
LVFWd, mm (median, 95% range) 4.0, 2.7; 7.2 4.0, 2.9; 5.8 0.70
IVSs, mm (median, 95% range) 6.6, 5.0; 12.4 6.7, 5.0; 9.0 0.82
LVIDs, mm (median, 95% range) 9.6, 3.9; 12.9 10.0, 6.3; 14.0 0.83
LVFWs, mm (median, 95% range) 7.0, 5.2; 9.2 7.0, 4.1; 9.8 0.08
LA/Ao, (median, 95% range) 1.0, 0.9; 1.3 1.0, 0.9; 1.4 0.06
% with murmur 7 0
% with SAM 7 0
% with obliteration 14 3
% with hypertrophic papillary muscle 7 12
% with increased LA 0 0
IVSd: diastolic intraventricular septum, LVIDd: diastolic left ventricular inner diameter, LVFWd: diastolic left ventricular free wall, IVSs: systolic intraventricular
septum, LVIDs: systolic left ventricular inner diameter, LVFWs: systolic left ventricular free wall, LA/Ao: left atrium over aorta.
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Again, no significant association between p.A31P
cMyBP-C and fHCM was found in heterozygous cats.
This again indicated that p.A31P cMyBP-C associated
fHCM was a disease with a very low penetrance also in
middle-aged cats heterozygous for the mutation and
highly penetrant for cats homozygous for the mutation.
We propose that the p.A31P cMyBP-C mutation results
in an inheritance patterns that resembles a recessive
form of inheritance in young MC cats.
However, the clinical significance of the heterozygous
mutation carrier status must be established in a cohort
of older cats before conclusions regarding mode of
inheritance are finalized and firm breeding recommen-
dations made. Therefore, follow-up studies of the cohort
are recommended with a delay of 2-5 years from this
study to evaluate the clinical course of the heterozygous
in respect to the probability of late-onset fHCM. Very
recently, Wess et al. [11] stated that the p.A31P muta-
tion is less pathogenic than reported so far based upon
a cohort of 82 MC cats (mean age approx. 70-72
months). However, we find the number of homozygous
cats in that study were too low (n = 3) to reliably assess
the fHCM risk associated with this genotype [11]. The
low number of homozygous cats might be the result of
fHCM-associated yearly death. That study supports our
results concerning heterozygous mutation carriers and
fHCM development. However, another study has
reported tissue Doppler imaging evidence of diastolic
dysfunction in MC cats heterozygous for the mutation
indicating that even though there may not be overt evi-
dence of fHCM there is evidence of occult fHCM in
these cats [10]. If occult disease is taken into considera-
tion then an autosomal dominant mode of inheritance
needs to be considered.
Figure 2 2-D echocardiographic recordings of papillary muscles from a normal and an fHCM affected cat. Left illustration: Right
parasternal short axis of the left ventricle with papillary muscles view from a normal MC cat. Middle illustration: Right parasternal short axis of
the left ventricle with papillary muscles view from a cat with severe hypertrophic cardiomyopathy. Right illustration: Gross heart specimen from a
cat with severe concentric hypertrophy due to fHCM. Figure abbreviations: IVS: Intraventricular septum, LV: left ventricle and PW: posterior wall
(free wall).
Figure 3 Illustration of M-mode echocardiographic recordings from a normal and an fHCM affected cat. Left illustration: M-mode
echocardiogram recorded from an MC cat at the level of chordae tendinae shows normal left ventricular internal dimension, septum and
posterior wall of the left ventricle. Right: M-mode echocardiogram from and an MC cat with severe fHCM with atrial fibrillation (HR 325/min),
congestive heart failure and tromboembolic disease, recorded at the level of the chordae tendinae to assess left ventricular dimensions shows
severe thickening of both the septum and posterior wall of the left ventricle. Figure abbreviations: IVS: Intraventricular septum, LV: left ventricle
and PW: posterior wall.
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Recessive, or gene dosage dependent, mode of inheri-
tance has previously been shown to be the case in some
human patients with cMyBP-C associated HCM [22]. It
can not be excluded that the p.A31P cMyBP-C mutation
may exhibit a dominant pattern of inheritance pattern in
a single colony of cats as previously described [4]. This
may be a consequence of various factors, which may
modify the phenotype. It is possible that those pedigrees
with cats heterozygous for the p.A31P mutation and
affected with fHCM may represent digenic inheritance
0%
20%
40%
60%
80%
100%
cMyBP-C wild type p.A31P cMyBP-C
heterozygous
p.A31P cMyBP-C
homozygous
0%
20%
40%
60%
80%
100%
cMyBP-C wild type p.A31P cMyBP-C heterozygous p.A31P cMyBP-C homozygous
Figure 4 Distributions of fHCM and equivocal cases in respect to p.A31P cMyBP-C genotype status. A: Histogram of the distribution for the
entire cohort. The group of p.A31P cMyBP-C homozygous cats had an increased proportion of fHCM cases. B. Histogram of the distribution for cats
over 4 years of age. Except for the homozygous the distribution was very similar to the distribution shown in A. Parts of boxes marked with small
dots represent fHCM negative cats. Blank parts of the boxes indicate equivocal cases. Box marked with black stripes indicate cases of fHCM.
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or compound heterozygosity where another yet undis-
covered mutation is present with the p.A31P cMyBP-C
mutation. Digenic or compound heterozygosity is pre-
sent in 8-30% of human HCM cases [13,15,23]. This
suggests the need to conduct a mutation screening of all
the HCM associated sarcomeric genes in MC cats.
Seven out of 21 MC cats with an fHCM diagnosis
were not carrying the mutation, revealing that the etiol-
ogy of fHCM is heterogeneous (i.e. at least one more
cause is present) in the MC breed. Human HCM is
associated with one or more mutations in at least 11
cardiac sarcomere genes [15]. In total, eight cardiac sar-
comere genes associated with human HCM have been
screened for fHCM disease-causing mutations in 14 cats
from five different breeds [24]. The study did not iden-
tify any new disease-causing mutations in the sarcomere
genes MYH7, MYBPC3, TNNT2, TNNI3, TPM1, MYL2,
MYL3 and ACTC. However, these genes should still be
considered as candidate genes for fHCM, as the cohort
used in the study is very small [24]. By analogy to
human HCM, it would seem very unlikely to identify
mutations in these genes in a small patient group as the
genes are - individually - rarely affected [13,15].
Defining a “normal heart” is a complicated clinical
task that involves serial measurements and collecting a
sufficient variety of pre-clinical and clinical information.
Each specific heart disease, in principle, needs a specific
reference interval or decision limits (cut-off points).
Decision limits for fHCM with diastolic LVFW and IVS
> 6 mm may impose difficulties in screening for fHCM
in phenotypically normal “carriers” or in cats with muta-
tions that cause late-onset fHCM. In early stages of dis-
ease, a high percentage of false negative results may be
the consequence of too high a cut-off point.
The group of equivocal MC cats may contain a high
number of both “false positive” and “false negative” cats.
The category contains cats with normal wall thickness
(< 5.5 mm) and papillary muscle hypertrophy, with or
without obliteration. Consequently, the term “equivocal”
was given to cats in which the heart showed some of
the echocardiographic signs suggestive of fHCM, but
without being distinctive enough to classify the cat as
fHCM positive. These cats were in a grey zone and
follow-up echocardiographic examination was always
recommended to this group.
The present reference interval was established in a
homogeneous MC population at large. No “normal”
female or male cats had wall thickness > 5 mm and only
three out of twenty-six equivocal cats were in the range
from 5-5.5 mm. Although a lowering of a decision limit
from 6 to 5.5 mm may cause slightly higher false posi-
tive results, we found that a 5.5 mm upper limit was a
more appropriate value for screening for fHCM. This
was a finding in agreement with a previous study where
5.0 mm is suggested as normal upper limit for myocar-
dial thickness in MC [9].
The p.A31P cMyBP-C genotype distribution was not in
Hardy-Weinberg equilibrium, indicating that there was a
bias of selection in the MC cohort. In addition, the dis-
equilibrium could possibly be explained by a reduced
number of homozygous cats, which supports that the p.
A31P cMyBP-C mutation was disease-causing and
resulted in an increased mortality even in young cats.
This is comparable with the findings in human HCM,
where an early clinical debut of HCM is associated with a
very poor prognosis [25]. Breeders volunteered their cats
to be enrolled in the study, thus breeders with no interest
in fHCM and fHCM genetics were not likely to partici-
pate. Furthermore, MC cats from breeding programs are
bred based on certain selection criteria. Breeders with a
commercial interest only use the strongest male and
female cats for reproduction. That the prevalence of
fHCM and of the p.A31P cMyBP-C mutation found in
our cohort is similar to previously reported prevalence
reduces bias though [9,16,26].Finally, only one-third of
the cats in our cohort were males, this bias may result in
underestimation of the fHCM prevalence, as fHCM is
more common in male cats.
Conclusions
In conclusion, p.A31P cMyBP-C associated fHCM is a
disease with very low penetrance in young heterozygous
cats. Our results support the pathogenic role of p.A31P
when two affected gene alleles are present in a MC cat.
Homozygosity of the cMyBP-C mutation only explained
43% of fHCM cases in the MC cohort therefore we
Table 5 The fHCM odds ratio and fHCM prevalence of the three genotype categories: heterozygous, homozygous and
the hetero- and homozygous combined
Genotype fHCM prevalence fHCM + equivocal prevalence fHCM Odds ratio* fHCM + equivocal odds ratio
All (G/G)+(G/C)+(C/C) 6.3% 14.2% - -
Heterozygous (G/C) 2.3% 12.8% 0.5 (95% Cfi: 0.1; 2.3) 0.8(95% Cfi: 0.3; 1.8)
Homozygous (C/C) 50% 61.1% 21.6 (95% Cfi: 7.0; 66.2) 12.1 (95% Cfi: 4.3; 33.9)
All carriers (G/C)+(C/C) 10.3% 19.8% 2.5 (95% Cfi: 1.0; 6.0) 2.9 (95% Cfi: 1.6; 5.5)
*The equivocal cats have been added to the non-affected cats.
In all three categories the odds ratio was calculated as compared to the group of wild type cats.
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recommend further large-scale genetic studies to iden-
tify potential disease-causing mutations in genes includ-
ing the sarcomere genes most commonly involved in
human HCM. Furthermore, due to the high probability
of developing fHCM in the p.A31P cMyBP-C homozy-
gous cats the ‘production’ of homozygous MC cats
should be avoided. Thus, although genotyping of the p.
A31P cMyBP-C mutation can not stand alone in limit-
ing fHCM in MC, it is very important that breeders are
aware of the genotype status and breeders should be
informed of breeding recommendations. Breeding
recommendations concerning this genetic variant are
still controversial.
List of abbreviations
c.91G > C: guanine substituted for a cytosine at the 91th nucleotide of the
coding gene sequence; Cfi: confidence interval; cMyBP-C: cardiac myosin
binding protein C; fHCM: feline HCM; HCM: Hypertrophic cardiomyopathy;
IVS: interventricular septum; LA/Ao: ratio of left atria diameter over aorta; LV:
left ventricle; LVFW: left ventricular free wall; LVID: left ventricular inner
diameter; MC: Maine Coon; p.A31P: alanine substituted for a proline at
residue 31; PW: posterior wall; OR: Odds ratio; SAM: systolic anterior
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